Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens

Virology

Volumn 428, Issue 2, 2012, Pages 121-127

  Santra, Sampa ^a   Muldoon, Mark ^b   Watson, Sydeaka ^c   Buzby, Adam ^a   Balachandran, Harikrishnan ^a   Carlson, Kevin R ^a   Mach, Linh ^a   Kong, Wing Pui ^d   McKee, Krisha ^d   Yang, Zhi Yong ^d   Rao, Srinivas S ^d   Mascola, John R ^d   Nabel, Gary J ^d   Korber, Bette T ^e,f   Letvin, Norman L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f SANTA FE INSTITUTE   (United States)

Author keywords

HIV 1 vaccine; Mosaic immunogen; T cell

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE SUBPOPULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MACACA MULATTA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA;

EID: 84860837935     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.03.012     Document Type: Article

References (30)

1. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., Sun Y.H., La Porte A., Riggs A.M., Lynch D.M., Clark S.L., Backus K., Perry J.R., Seaman M.S., Carville A., Mansfield K.G., Szinger J.J., Fischer W., Muldoon M., Korber B. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 2010, 16(3):319-323.
2. Barouch D.H., Yang Z.Y., Kong W.P., Korioth-Schmitz B., Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Miura A., Mascola J.R., Letvin N.L., Nabel G.J. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 2005, 79(14):8828-8834.
3. Einfeld D.A., Schroeder R., Roelvink P.W., Lizonova A., King C.R., Kovesdi I., Wickham T.J. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 2001, 75(23):11284-11291.
4. Ferre A.L., Lemongello D., Hunt P.W., Morris M.M., Garcia J.C., Pollard R.B., Yee H.F., Martin J.N., Deeks S.G., Shacklett B.L. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J. Virol. 2010, 84(19):10354-10365.
5. Fischer W., Liao H.X., Haynes B.F., Letvin N.L., Korber B. Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput. Biol. 2008, 4(1):e15. author reply e25.
6. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., Kuiken C., Haynes B., Letvin N.L., Walker B.D., Hahn B.H., Korber B.T. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007, 13(1):100-106.
7. Grard G., Biek R., Tamfum J.J., Fair J., Wolfe N., Formenty P., Paweska J., Leroy E. Emergence of divergent Zaire ebola virus strains in Democratic Republic of the Congo in 2007 and 2008. J. Infect. Dis. 2011, 204(Suppl 3):S776-S784.
8. Huang Y., Kong W.P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 2001, 75(10):4947-4951.
9. Kong W.P., Wu L., Wallstrom T.C., Fischer W., Yang Z.Y., Ko S.Y., Letvin N.L., Haynes B.F., Hahn B.H., Korber B., Nabel G.J. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J. Virol. 2009, 83(5):2201-2215.
10. Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 2009, 83(17):8300-8314.
11. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(16):10108-10125.
12. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 2005, 79(16):10103-10107.
13. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
14. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 1996, 70(11):7498-7509.
15. Ndhlovu Z.M., Piechocka-Trocha A., Vine S., McMullen A., Koofhethile K.C., Goulder P.J., Ndung'u T., Barouch D.H., Walker B.D. Mosaic HIV-1 gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J. Immunol. 2011, 186(12):6914-6924.
16. Nunes A., Noqueira P.J., Borrego M.J., Gomes J.P. Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-cell epitopes: worldwide survey. PloS One 2010, 5(10):e13171.
17. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The N. Engl. J. Med. 2009, 361(23):2209-2220.
18. Santra S., Korber B.T., Muldoon M., Barouch D.H., Nabel G.J., Gao F., Hahn B.H., Haynes B.F., Letvin N.L. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc. Natl. Acad. Sci. USA 2008, 105(30):10489-10494.
19. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., Theiler J., Szinger J., Balachandran H., Buzby A., Quinn D., Parks R.J., Tsao C.Y., Carville A., Mansfield K.G., Pavlakis G.N., Felber B.K., Haynes B.F., Korber B.T., Letvin N.L. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 2010, 16(3):324-328.
20. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., Gorgone D.A., Beaudry K.R., Svehla K., Welcher B., Chakrabarti B.K., Huang Y., Yang Z.Y., Mascola J.R., Nabel G.J., Letvin N.L. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 2005, 79(10):6516-6522.
21. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84(3):1439-1452.
22. Shi M., Lam T.T., Hon C.C., Murtaugh M.P., Davies P.R., Hui R.K., Li J., Wong L.T., Yip C.W., Jiang J.W., Leung F.C. Phylogeny-based evolutionary, demographical, and geographical dissection of North American type 2 porcine reproductive and respiratory syndrome viruses. J. Virol. 2010, 84(17):8700-8711.
23. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415(6869):331-335.
24. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., Lifton M.A., Koudstaal W., Pau M.G., Kostense S., Havenga M.J., Goudsmit J., Letvin N.L., Barouch D.H. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 2004, 78(6):2666-2673.
25. Thurmond J., Yoon H., Kuiken C., Yusim K., Perkins S., Theiler J., Bhattacharya T., Korber B., Fischer W. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 2008, 24(14):1639-1640.
26. Wu L., Kong W.P., Nabel G.J. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J. Virol. 2005, 79(13):8024-8031.
27. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
28. Wu X., Zhou T., O'Dell S., Wyatt R.T., Kwong P.D., Mascola J.R. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 2009, 83(21):10892-10907.
29. Yang Z.Y., Wei C.J., Kong W.P., Wu L., Xu L., Smith D.F., Nabel G.J. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 2007, 317(5839):825-828.
30. Yusim K., Fischer W., Yoon H., Thurmond J., Fenimore P.W., Lauer G., Korber B., Kuiken C. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J. Gen. Virol. 2010, 91(Pt 5):1194-1206.